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Abstract
Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer
(GC) patients developed recurrences. The aim of this study was to develop and validate a prognostic algorithm for gastric
cancer (GCPS) that can robustly identify high-risk group for recurrence among stage II patients. A multi-step gene
expression profiling study was conducted. First, a microarray gene expression profiling of archived paraffin-embedded
tumor blocks was used to identify candidate prognostic genes (N= 432). Second, a focused gene expression assay including
prognostic genes was used to develop a robust clinical assay (GCPS) in stage II patients from the same cohort (N = 186).
Third, a predefined cut off for the GCPS was validated using an independent stage II cohort (N = 216). The GCPS was
validated in another set with stage II GC who underwent surgery without adjuvant treatment (N = 300). GCPS was
developed by summing the product of Cox regression coefficients and normalized expression levels of 8 genes (LAMP5,
CDC25B, CDK1, CLIP4, LTB4R2, MATN3, NOX4, TFDP1). A prospectively defined cut-point for GCPS classified 22.7% of
validation cohort treated with chemoradiotherapy (N= 216) as high-risk group with 5-year recurrence rate of 58.6%
compared to 85.4% in the low risk group (hazard ratio for recurrence = 3.16, p = 0.00004). GCPS also identified high-risk
group among stage II patients treated with surgery only (hazard ratio = 1.77, p = 0.0053).
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Introduction
Gastric cancers are highly lethal malignancies with five-year
survival rates being one of the worst reported for any solid tumors.
According to data from the National Cancer Institute Surveil-
lance, Epidemiology and End Results (SEER) Program, the five-
year survival for patients with gastric cancer (GC) improved only
modestly over the last 50 years, from 12 to 22 percent [1]. The
propensity of GC for early metastatic dissemination has been well
documented in previous studies [2,3]. Based on the recent
adjuvant phase III trials, survival benefit from adjuvant chemo-
therapy or chemoradiation therapy has been documented in GC
[4–7]. However, 25 to 40% of all surgically resected GC patients
still develop recurrences that are not amenable to re-resection
[4,7–9]. For pathologic stage III and IV GC, 5-year disease-free
survival rates are very poor (stage IIIA, 57.6%, stage IIIB, 39.6%;
and stage IV 26.3%) [8] implicating that these tumors have
inherently aggressive behaviour. In contrast, pathologic stage II
GC patients have more favorable clinical outcome with 5-year
disease free survival rates of 76% 290% following surgery and
adjuvant treatment [8,9]. Nevertheless, there is a wide spectrum of
clinical aggressiveness even within the same stage with some
patients being cured with surgery alone while some patients recur
shortly after surgery and adjuvant chemoradiation therapy.
Hence, based on the hypothesis that there is a significant
molecular heterogeneity, we designed a large-scaled gene expres-
sion profiling study to develop a molecular test which may
efficiently discriminate low-risk from high-risk GC groups for
recurrence after surgery.
A molecular test that identifies high-risk patients for recurrence
may lead to optimized perioperative treatment strategies in GC.
The discovery phase included GC patients from all clinical stages
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treated with chemoradiotherapy (N= 520). Tumor blocks from
these patients were subjected to prognostic gene discovery using
Whole Genome DASL assay (WG-DASL) (Illumina, San Diego,
CA), a microarray gene expression profiling method for formalin-
fixed paraffin-embedded tissue (FFPE). The purpose was to
develop hypothesis for clinical utility and discover candidate
prognostic or internal reference genes that will help design focused
gene expression assay. Results from this phase suggested that
clinical utility of a gene expression based prognostic algorithm may
potentially distinguish a high-risk group among stage II patients.
The objective of the project was to develop a hypothesis with
clinical utility and discover candidate prognostic or internal
reference genes in order to design focused gene expression assays.
The results from the discovery phase suggest that clinical utility of
a gene expression-based prognostic algorithm may potentially
distinguish a high-risk group among stage II patients. With the use
of a robust multistep prognostic algorithm, Gastric Cancer
Prognostic Score (GCPS) for stage II GC patients was developed
to identify high-risk patients for recurrence after surgery.
Methods
From September 1994 to December 2005, 1,557 GC patients
underwent curative gastrectomy at Samsung Medical Center.
Among those, 1,107 patients were selected based on following
criteria: histologically confirmed adenocarcinoma of the stomach;
surgical resection of tumour without macroscopic or microscopic
residual disease; age $18; pathology stage IB (T2bN0, T1N1 but
not T2aN0) to IV, according to the American Joint Committee on
Cancer (AJCC) staging system (6th Ed); complete surgical record
and treatment record, and patients receiving the INT-0116
regimen as adjuvant treatment [7]. The study was approved by
the institutional review board of the Samsung Medical Center,
Seoul, South Korea (IRB approval number: SMC 2010-10-025).
All study participants provided written informed consent form
recommended by the IRB. In the patients who have deceased at
the time of study entry, written informed consent forms were
waived by the IRB. Study design and patient cohorts are provided
according to REMARK guideline (Figure 1A, 1B, File S1,
Section 1). Of the cohort of 1,107 patients, a discovery set of 520
patients and a validation set of 587 patients were randomly
assigned and allocated to 6 batches stratified by tumor size and
year of surgery for WG-DASL assay.
To avoid false-positive conclusions due to over-fitting, prognos-
tic algorithms and their predefined cut-points were tested in
independent cohorts that were not used for prognostic gene
discovery and algorithm building. A 4-phase study was designed,
with 4 pre-defined independent cohorts recruited from the
Samsung Medical Center. The first 3 cohorts include patients
with similar clinical and pathological features from chemora-
diotherapy-treated study cohorts (File S1, Section 2). The first
phase (discovery phase) of the study included GC patients
from all clinical stages who were treated with chemo-radiotherapy
(N= 520) [8]. Tumor blocks from these patients were subjected to
prognostic gene discovery using the WG-DASL (Illumina, San
Diego, CA), a microarray gene expression profiling method for
FFPE [7]. An ad-hoc external validation of the gene set was
performed to minimize any bias from single institutional cohort.
The second phase (algorithm development) was to translate
findings from the first phase into a clinically applicable test format.
We chose the nCounter platform (Nanostring Technologies,
Seattle, WA), because of its ability to interrogate the expression
levels of up to 800 genes using total RNA extracted from FFPE in
a single-tube reaction [8]. We screened stage II patients from the
first phase (N= 186) for de novo discovery of prognostic genes,
selected ideal combinations of genes using the gradient least
absolute shrinkage and selection operator (LASSO) algorithm
[10], and then built a first-generation GCPS (GCPS-g1) by adding
the products of normalized gene expression and coefficients from
the Cox model for DFS. In the third cohort of stage II patients
(N= 216). In the fourth phase (testing of clinical utility in a
surgery-only setting), we tested the potential clinical utility of
GCPS in stage II patients treated with surgery only. A time stamp
protocol (Figure S12) was developed before processing of this
final cohort. We subsequently developed a refined second-
generation GCPS (GCPS-g2) (the final gene set) by analyzing
the combined stage II cohorts from the second and third phases of
the study.
Gene expression profiling using whole genome-DASL
assay
Before each gene profiling experiment, tissue samples were
randomly allocated to different batches stratified by surgery time
(before 2000 vs. after 2000) and tumor size (#5 cm vs .5 cm) to
minimize any variations from the DNA quality. Total RNA was
extracted from 2–4 sections of 4-mm thick FFPE sections from
representative primary tumor blocks using the High Pure RNA
Figure 1. The Consort Diagram. (A) A multi-step approach gene expression profiling design, (B) Consort Diagram.
doi:10.1371/journal.pone.0090133.g001
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Paraffin kit (Roche Diagnostic, Mannheim, Germany) after
removing non-tumor elements by manual macrodissection guided
by hematoxylin and eosin stained slides. WG-DASL assay was
performed using 200 ng of RNA following the manufacturer’s
instruction [11]. For nCounter assay, 200 ng of total RNA was
hybridized with the custom designed code set of 800 genes for
18 hours at 65uC and processed according to manufacturer’s
instruction [12]. The data were normalized to average expression
levels of 48 internal reference genes selected from microarray
experiment. The detailed description of the discovery phase using
WG-DASL assay is provided in File S1, Section 3. The
comparability in DNA quality of FFPE tissue and fresh frozen
tissues using DASL assay was published previously [13,14].
Prognostic model building and validation
The algorithm for n-Counter-based assay development for
clinical utility based on WG-DASL is provided in File S1,
Sections 4–6. We used the gradient lasso algorithm to fit a
prediction model based on Cox’s proportional hazards model for
DFS using the probes with marginal p value,0.01 (Figure S2 in
File S1) [10]. We used leave one out cross validation with de novo
discovery at each leave one out step to assess the performance of
the prognostic model within the discovery cohort. Optimal cut-
point was determined by creating a plot for p-values for each cut-
point for the prognostic score. For validation study, a priori
defined algorithm and cut-point values were used. The validation
method for GCPS is outlined in File S1, Section 7.
Results
Microarray gene expression profiling of GC patients
treated with adjuvant chemoradiotherapy (phase 1)
We performed gene expression profiling of FFPE from the
discovery cohort of 520 cases of stage IB–IV GC treated with
standard chemoradiotherapy after curative resection using the
WG-DASL assay (Figure 1). Among them, 432 samples passed
RNA quality control (GEO database GSE 26253) (File S1,
Section 3). The primary end point was DFS. Univariate analysis
identified 369 probes that were significantly associated with
disease-free survival at p,0.01 without adjustment for other
clinical variables (File S1, Section 3d). Next, gradient Lasso was
used to develop a prognostic algorithm to predict recurrence (File
S1, Section 3e). The leave-one-out cross-validation (LOOCV)
procedure with de novo discovery of prognostic genes and the
building of a prognostic algorithm at each step was used to
examine the robustness of the prognostic algorithm. According to
prognostic gene signatures (26 genes, File S1, Section 3f) and
pathologic stages (localized vs. advanced), 432 patients were
categorized into the following groups: low-risk and stage IB/II
(N= 145; 5-year DFS, 84.8%), high-risk and stage IB/II (N= 90;
5-year DFS, 61.1%), low-risk and stage III/IV (N= 83; 5-year
DFS, 48.9%), and high-risk and stage III/IV (N= 114; 5-year
DFS, 36.9%) (Figure 2). As an ad-hoc analysis, we tested this
gene signature using gene expression profiling data from the
Singapore patient cohort (N= 199) to minimize any inherent bias
from a single institution cohort [15]. In the external patient cohort,
the gene signature was able to separate the high-risk group
(N= 100) from the low-risk group (N= 99) for recurrence with
statistical significance (p,0.00001; hazard ratio (HR), 2.3; 95%
CI, 1.62–3.28) (Figure 2). These data suggest the main clinical
utility of gene expression profiling of GC in the identification of
high-risk patients among stage II patients (low vs. high risk stage
IB/II, 84.8% vs. 61.1%; low vs. high risk stage III/IV, 48.9% vs.
36.9%). Therefore, for the development of clinical assay and
validation, we focused on developing a gene-set which can robustly
predict recurrence in stage II patients.
Development of Gastric Cancer Prognostic Score (GCPS)
for stage II GC using the nCounter assay (phase 2)
We custom designed an nCounter probe set comprised of
candidate prognostic genes from WG-DASL microarray data
(phase 1), as well as known cancer genes, kinase genes, and G
protein-coupled receptor genes. To address the variability problem
in the integrity of RNA molecules in archived FFPE due to pre-
analytical variables, such as fixation time and age of the blocks, we
applied within-sample normalization using a set of 48 internal
reference genes selected from microarray data based on minimum
variation across cases and lack of association with prognosis (File
S1, Section 4). Correlation between hazard ratios of prognostic
genes based on nanostring and WG-DASL are provided in File
S1, Section 4b, and Figure S3 in File S1.
We profiled 186 stage II patients from the discovery set. After
assessing the robustness of prognostic algorithms built by gradient
LASSO through LOOCV, we applied gradient LASSO to all 186
Figure 2. Kaplan-Meier curves for high risk and low risk groups classified by leave one out cross validation procedure. HR denotes
hazard ratio and p-value is calculated from 100 permutations. (A) all stage patients, high vs low risk; (B) according to stage and risk groups; (C)
External validation of the initial gene expression profiling.
doi:10.1371/journal.pone.0090133.g002
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patients and identified 8 genes (LAMP5, CDC25B, CDK1,
CLIP4, LTB4R2, MATN3, NOX4, and TFDP1) that in
combination provided robust prognostic information (Table 1).
The GCPS was then developed as a linear combination of the Cox
regression estimates and normalized expression levels of these 8
genes. The cut-point analysis demonstrates that the GCPS was
most robust in identifying 25% of patients with worst outcomes
(File S1, Section 4). We chose a cut-point of 0.2205 for
prospective validation in the independent validation cohort.
Validation of GCPS and its predefined cut-point in stage II
GC patients treated with chemoradiotherapy (phase 3)
To avoid the potential over-fitting issue associated with cross-
validation [16], we validated GCPS with the fixed algorithm and
cut-points in an independent patient cohort that was not used in
gene discovery. The clinical and pathological features of 216 stage
II patients from the validation set were similar to those from the
discovery cohort (File S1, Section 6, and Figures S4–6 in File
S1). When we applied GCPS-g1 to the validation set, the risk score
distribution was very similar, suggesting the robust analytical
performance of the assay (File S1, Section 7a, and Figure S7 is
File S1). The predefined cut-point (0.2205) for GCPS-g1 classified
22.7% of tumors from the validation set as the high-risk group.
The Kaplan Meier estimate of 5-year DFS for the high-risk
patients was 58.6%, compared to 85.4% for the low-risk patients
(HR for recurrence, 3.16; p = 0.00004) (Figure 3). GCPS was
significant in both intestinal- and diffuse- type GCs, as shown in
Figure S8 in File S1 (File S1, Section 7b). The multivariate
analysis further shows that GCPS-g1 provided additional prog-
nostic information, besides other known factors such as Lauren
classification, differentiation grade, age, and surgery type (HR,
3.027; p = 0.00016; Table 2). Therefore, GCPS may be used to
identify stage II patients who remain at high risk even after
standard adjuvant chemoradiotherapy and who have similar risk
of recurrence as stage III patients.
GCPS as a prognostic factor for stage II GC patients
treated with surgery only based on a prospectively
designed protocol (phase 4)
The review of the clinical database identified 306 patients who
did not receive postoperative treatment based on shared decision
between physicians and patients (File S1, Section 1, Table S1
in File S1). These patients were subjected to exploratory analyses
for assessing the prognostic role of GCPS in patients treated with
surgery only and testing the hypothesis that the benefit from
chemoradiotherapy is limited in high-risk patients defined by
GCPS. For this step, we developed GCPS-g2 (Table S8 in File
S1), the second-generation GCPS, by analyzing all stage II cases
from phases 2 and 3 to maximize the sample size. We
prospectively tested the predefined GCPS-g2 algorithm and cut-
point as described in the time stamp protocol (Figure S12 in File
S1). The GCPS-g2 predicted recurrence in 300 stage II tumors
with a hazard ratio of 2.131 (95% CI, 1.428–3.180; p = 0.00021)
(HR, 3.16) (Figure S9 in File S1). To minimize the possibility of
over-fitting of the algorithm to chemoradiotherapy-treated pa-
tients, we also tested the GCPS-g1, which was previously validated
in the chemoradiotherapy-treated cohort, in surgery alone cohort
(Figure S10 in File S1). The hazard ratio for GCPS-g1 (HR,
1.77; 95% CI, 1.18–2.67; p = 0.0053) is similar to that for GCPS-
g2 (Figure 3). Therefore, the GCPS robustly predicted recurrence
in stage II GC with or without postoperative treatment. Based on
this data, it can be speculated that high-risk stage II patients
defined by GCPS did not gain a tremendous benefit from
chemoradiotherapy.
Expression of adverse prognostic genes in tumor
microenvironments
In all 3 stage II cohorts included in this study, increased
expression levels of 4 genes from GCPS (NOX4, LAMP5,
MATN3, and CLIP4) were associated with poor prognosis. Since
the known functions of these genes suggest their expression in
microenvironments rather than actual tumor cells, we performed
the nCounter assay for microdissected tumors versus stromal
components from 4 representative high-risk tumors (Figure S11
in File S1). The expression of these genes was significantly higher
in stromal components, compared to epithelial cancer cells, with
NOX4 showing the most pronounced differences (p = 0.04).
Discussion
In an initial discovery phase, we performed WG-DASL in all
stage GC patients. Then, based on the WG-DASL data, we
observed that the segregation of high risk group from low risk
group was most significant in early stage Ib/II patients (low vs.
high risk stage IB/II, 84.8% vs. 61.1%; low vs. high risk stage III/
IV, 48.9% vs. 36.9%). Therefore, for the development of clinical
assay and validation, we focused on developing a gene-set which
can robustly predict recurrence in stage II patients. We developed
Table 1. List of genes that constitute Gastric Cancer Prognostic Score and their Cox regression estimates used to calculate the
score.
Gene Symbol Chromosomal location Gene Name Cox regression estimate
LAMP5(BAD-LAMP, C20orf103) 20p12 Lysosomal-associated membrane protein family,
member 5
0.0636
CDC25B 20p13 Cell division cycle 25 homolog B (S. pombe) 20.0175
CDK1 10q21.1 Cyclin-dependent kinase 1 20.1005
CLIP4 (UBASH3A, TULA, STS-2, TULA-1) 2p23.2 CAP-GLY domain containing linker family, member 4;
Suppressor of T cell receptor signaling-2
0.4822
LTB4R2 14q11.2-q12 Leukotriene B4 receptor 20.3950
MATN3 2p24-p23 Matrillin 3 0.2982
NOX4 11q14.2-q21 NADPH oxidase 4 0.0288
TFDP1 13q34 Transcription factor Dp-1 20.2886
doi:10.1371/journal.pone.0090133.t001
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and validated a prognostic algorithm for gastric cancer, GCPS,
which can robustly identify high-risk groups for recurrence among
stage II patients. GCPS, developed using the nCounter platform,
showed the robust performance in FFPE samples. In addition, the
inclusion of internal reference genes allowed the application of
GCPS to individual patients. Therefore, we suggest that GCPS
can be readily applied to routine clinical use. The GCPS of 8
genes (LAMP5, CDC25B, CDK1, CLIP4, LTB4R2, MATN3,
NOX4, and TFDP1) were discovered and validated in over 700
stage II GC patients. We found that the GCPS identified high-risk
GC patients for recurrence regardless adjuvant treatment and that
high-risk stage II GC patients showed similar DFS to stage III
patients. Notably, the GCPS predicted recurrence of both Lauren
types (diffuse or intestinal) (Figure S8 in File S1).
Our data clearly demonstrate the presence of molecular
heterogeneity in GC, which was associated with clinical outcomes
but independent of clinicopathologic staging information. Our
data indicate that stage IB/II patients had very poor prognosis
when their tumors expressed poor-risk gene signatures. There was
a difference of 23.7% in 5-year DFS between high-risk and low-
risk gene signatures in stage IB/II patients, and 5-year DFS of
high-risk stage IB/II patients was below 60%, despite the use of
adjuvant chemoradiotherapy (Figure 1). Therefore, it may be
necessary to prospectively design a trial to question whether
chemoradiotherapy is required for stage IB/II patients with low-
risk gene expression profiles. In order to minimize any potential
bias from variations in clinical practice or surgery at a single
center, we performed an ad hoc external validation of the
signature to validate the signature. As shown in the Results, the
signature consistently predicted recurrence in Singapore cohort.
Among the 8 final GCPS genes (LAMP5, CDC25B, CDK1,
CLIP4, LTB4R2, MATN3, NOX4, and TFDP1), CDC25B and
CDK1, which are known to be associated with cell proliferation,
were found to correlate with favorable prognosis (negative Cox
regression estimates in Table 2). Notably, a similar trend has been
observed for colon cancer by a gene expression assay [17,18].
These findings may reflect the differentiation status of these tumor
cells, since normal gastric and colon mucosal epithelial cells have
high turnover rates. TFDP1 encodes the transcriptional factor DP-
1, which acts as a positive regulator of the G1/S transition during
the cell cycle [19,20]. Particularly in hepatocellular carcinoma,
TFDP1 overexpression was substantially associated with disease
progression [19]. Since the scope of this current study does not
include the functional study of these genes, their biological
significance should be investigated in future studies. Recently, Cho
et al. has performed the largest gene expression profiling in 213 GC
patients using fresh frozen tissues [21]. They identified 6
prognostic genes (CTNBB1, EXOCS3, TOP2A, LBA1, CCL5,
and LZTR1) for patient survival after curative resection. However,
to the best of our knowledge, GCPS is the only gene set which has
now been validated in more than 700 stage II GC patients,
regardless Lauren classification (diffuse or intestinal), a known
prognostic factor, or adjuvant treatment.
In conclusion, with the use of a multistep approach, we
developed 8-gene GCPS, which was able to robustly identify high-
risk stage II GC patients for recurrence after surgery regardless of
adjuvant treatment. Currently, with the ongoing ARTIST-II trial
(NCT#01761461), we plan to validate our GCPS in a prospec-
tively designed phase III trial.
Supporting Information
File S1 1. Patient characteristics of study cohorts at each step
(Table S1). a. Table S1. Patients characteristics. 2. Clinical and
pathological characteristics of cases examined at each phase. 3.
Detailed description of the discovery step using WG-DASL assay
(step 1). a. Figure S1. QA of WG-DASL data. b. Table S2.
Comparison of FISH and IHC results for HER2 status in gastric
cancer in Step 1. c. Table S3. List of probes that are differentially
Figure 3. (A) DFS of stage 2 patients according to GCPS. (B) DFS of stage 2 patients treated with surgery according to GCPS.
doi:10.1371/journal.pone.0090133.g003
Table 2. Multivariate Cox regression analysis results on the
validation set (N= 216).
Hazard ratio P-value
GCPS (low vs high-risk) 3.027 0.00016
LAUREN (intestinal vs diffuse) 0.541 0.18000
WHO (W/D,M/D vs P/D*) 2.491 0.07600
AGE (65,= vs 65.) 1.496 0.19000
Surgery types (subtotal vs total gastrectomy) 1.121 0.71000
*W/D, well differentiated; M/D, moderately differentiated; P/D, poorly
differentiated.
doi:10.1371/journal.pone.0090133.t002
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expressed between HER2-positive and HER2- negative patient
groups in Step 1. d. Table S4. List of all probes with univariate p-
values,0.01 in Step 1. e. Figure S2. Gradient Lasso algorithm. f.
Table S5. List of 26 probes included in the prediction model
fitted by the whole data set (n = 432). g. Table S6. Multivariate
Cox regression analysis results in gene discovery set (n = 432). 4.
Design of focused gene expression assay using nCounter platform.
a. Table S7. List of reference genes for nCounter assay. b.
Figure S3. Correlation between hazard ratios of prognostic genes
based on quantile normalization and self-normalization using
WG-DASL assay. 5. nCounter assay and quality control. 6.
Selection of cut-off for Gastric Cancer Prognostic Score
(GCPS(Figure S4, S5, & S6). a. Figure S4. DFS according to
each quartiles of GCPS-g1. b. Figure S5. Cut-point analysis for
GCPS-g1. c. Figure S6. DFS according to optimized cut-point of
GCPS-g1. 6. Distribution of GCPS between discovery set and
validation set. a. Figure S7. Distribution of GCPS-g1 within the
discovery and validation set. b. Figure S8. GCPS: intestinal vs
diffuse type. 7. Testing of clinical utility of GCPS-g2 in patients
treated with surgery only. a. Figure S9. DFS of stage II patients
treated with chemoradiotherapy based on quartile of GCPS-g2. b.
Figure S10. DFS of stage II patients treated with surgery alone
based on quartile of GCPS-g2. c. Figure S11. Expression of
adverse prognostic genes included in Gastric Cancer Prognostic
Score according to tissue compartments (tumor versus stroma).
Normalized expression levels are shown. d. Table S8. List of
nCounter probes included in GCPS-g2. 8. Gastric cancer
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